HZHuixin Anna Zhang

Huixin Anna Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Huixin Anna Zhang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative Outcomes of Standalone Xen63 Gel Stent and Preserflo Microshunt Implantation: A Multicenter Study

    by Ticiana De Francesco, Huixin Anna Zhang, Vital P Costa, Iqbal Ike K Ahmed

    Purpose: To evaluate the intraocular pressure (IOP)-lowering efficacy and adverse event profile of Xen63 gel stent compared to the Preserflo microshunt. Methods: Retrospective, multicenter, two-arm cohort study comparing 65 eyes undergoing standalone Xen63 implantation and 75 eyes undergoing standalone Preserflo implantation, all with intraoperative mitomycin C (MMC). Primary outcome was complete success, defined as all of the followings: 1) no two consecutive IOP readings > 17mmHg, 2) ≥ 20% IOP reduction from baseline; 3) no clinical hypotony (IOP < 6 mmHg associated with loss of ≥ 2 lines of vision); and 4) no use of glaucoma medications. Secondary outcomes included success at different IOP cut offs, qualified success (allowing medications), change in IOP, medications, complications, interventions, and re-operations. Results: At 12 months, complete success was achieved in 61.5% of eyes in the Xen63 group and 73.9% in the Preserflo group (p = 0.13). Postoperative complications were more frequent in the Xen63 group compared with the Preserflo group (61.5% vs. 29.3%, p = 0.0002). Postoperative interventions were required at similar rates between groups (Xen63 30.8% vs. Preserflo 28.0%, p = 0.85); however, reoperations were performed more frequently in the Xen63 group (16.9% vs. 4.0%, p = 0.01). Non-Caucasian ethnicity was associated with an increased risk of surgical failure (HR 2.57; 95% CI, 1.26– 5.23). Conclusion: Both devices achieved comparable success rates, median IOP reduction, and postoperative medication burden; however, the Xen63 group experienced a higher rate of complications and reoperations.

  • Open Access

    Association of rural or urban status, region, and institution type with cataract surgery wait times in Ontario, Canada

    by Huixin Anna Zhang, Marko M. Popovic, Nishaant Bhambra, Mack Hurst, Lori M. Diemert, Casey Chu, Mike Yang, Sherif El-Defrawy, Iqbal Ike K. Ahmed, Laura C. Rosella, et al.

  • Open Access

    Immune checkpoint inhibitor-associated Vogt-Koyanagi-Harada-like syndrome: A descriptive systematic review

    by Huixin Anna Zhang, Amelia T. Yuan, Noémie Chiasson, Kevin Y. Wu, Ananda Kalevar

    Topic: Vogt-Koyanagi-Harada (VKH)-like uveitis is uniquely reported with immune checkpoint inhibitors (ICI) and BRAF/MEK inhibitors. This article aims to provide a comprehensive portrait of the comorbidities, ocular presentations, treatments, and visual outcomes of patients with VKH-like uveitis following ICI therapy. Clinical relevance: ICIs are increasingly used in cancer therapy, but poorly understood ocular immune-related adverse events (irAEs) can lead to suspension of treatment and be vision-threatening. Methods: We conducted a systematic review (PROSPERO #CRD42024558269) according to PRISMA guidelines. MEDLINE, Embase, CENTRAL, and Web of Science were searched for English articles published up to June 28, 2024. All study designs reporting on incident VKH-like uveitis following ICI were included. Risk of Bias was assessed using a tool modified from Murad et al. (2018). Results: Of 865 articles, we included 42 articles (4 observational studies, 28 case reports, 6 case series, 3 letters, and 1 editorial) from 12 countries, comprising 52 patients. The mean age was 60.0 ± 11.9 years, and 32 (61.5%) were females. Thirty-six (69.2%) had melanoma, and most were undergoing treatment with a PD-1 inhibitor alone (n = 33, 63.5%) or in combination with a CTLA-4 inhibitor (n = 10, 19.2%). The mean duration of ICI treatment before VKH-like uveitis symptoms was 22.2 ± 29.6 weeks, and the mean duration of ocular symptoms was 16.7 ± 18.6 weeks, with wide variation. Overall, 43 patients (73.1%) had imaging or exams suggesting bilateral involvement and 21 cases (40.4%) suggesting panuveitis. Only 31 cases (59.6%) met the acute initial-onset uveitis criteria, and 15 (28.8%) met the chronic phase criteria. Most (n = 47, 90.4%) required systemic or intravitreal steroids, termination of ICI (n = 31, 59.6%), and experienced full resolution or remission of visual symptoms (n = 43, 82.7%). Most articles (n = 40, 95.2%) were judged to be at medium risk of bias. Conclusion: This descriptive systematic review consisted mostly of case reports, but it confirmed that a high proportion of VKH-like uveitis occur with PD-1 inhibitors and melanoma patients. VKH-like uveitis can lead to suspension of treatment. Further collaboration between oncologists and ophthalmologists is needed in the continuum of cancer care.


  • Cytokine levels in patients (pts) with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function

    by J. L. Vardy, C. Booth, G. R. Pond, H. Zhang, J. Galica, H. Dhillon, S. J. Clarke, I. F. Tannock

    9070 Background: Cytokines have been associated with fatigue and cognitive dysfunction. Here we evaluated plasma cytokine levels in pts with colorectal cancer (CRC) and breast cancer (BC) who were free of evident disease, and in healthy volunteers. Methods: Serum levels of 10 cytokines were measured using a LiquiChip assay on 251 subjects. CRC pts (n=136, ages 23–75) were evaluated at baseline (mean 8 weeks post-surgery [n=107] or before surgery [n=29]), with repeat measures at 6 months (56 post chemotherapy [CT], 14 without CT) and 12 months (32 post CT, 7 without CT). BC pts (n=51, ages 29–60) were within 5 years of diagnosis (33 after adjuvant CT). Healthy volunteers (n=64) had ages 20–62. Cancer pts completed questionnaires for fatigue & QOL (FACT-F), anxiety/depression (GHQ), and perceived cognitive function (FACT-COG); they had neuropsychological assessment. Results: Cytokines were elevated in all cancer groups compared to healthy controls (p-values <0.001; selected data in table ). Values were highest after surgery but remained significantly higher than healthy controls at 6–60 months after diagnosis, with a trend to being higher in cancer patients who had not received CT. There was a trend to elevated cytokines being associated with greater fatigue and cognitive impairment in both CRC and BC, but no association with QOL or anxiety & depression. Conclusions: Cytokine levels were elevated in all cancer groups compared to healthy volunteers and remained elevated up to 5 years post diagnosis; they may be associated with cognitive dysfunction and fatigue. [Table: see text] No significant financial relationships to disclose.